A Phase 2a, Multicenter, Randomized, Double-blind, Placebo Controlled and Active-controlled, Parallel-group Study Evaluating the Analgesic Efficacy and Safety of VM902A in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs VM 902 (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Purdue Pharma
- 20 Nov 2017 Status changed from suspended to discontinued.
- 29 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2018.
- 29 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 May 2018.